Fenbendazole for Liver Cancer: Potential Benefits, Current Research, and Safety Considerations

Fenbendazole started life as a dewormer for dogs, horses, and cattle. Over the last few years, it has picked up a second reputation online as a cheap drug that might fight cancer. There's a grain of truth in that. Some lab studies have found it can slow cancer cells down. But nobody has shown it treats liver cancer in people, and there are published reports of it damaging the liver. So it's worth slowing down and looking at what the research actually says.

What Is Fenbendazole?

Fenbendazole is an antiparasitic drug, part of a family called benzimidazoles that kill worms. Vets have used it in animals for decades. A couple of its relatives, mebendazole and albendazole, are approved for people. Fenbendazole isn't. The American Cancer Society says the FDA has never approved it for humans for any purpose, and because nobody has run proper human studies, we know very little about how the body handles it or whether it's safe over time.

That gap matters more than it sounds. A veterinary product is tested for animals, at animal doses. Nobody has done that homework for people.

Why Is Fenbendazole Being Studied for Cancer?

The interest starts with how the drug kills worms. It latches onto a protein called tubulin, which cells use to build their internal scaffolding, and without that scaffolding, a cell can't divide. Some well-known chemotherapy drugs, like vincristine and paclitaxel, also work by messing with tubulin. So researchers wondered whether fenbendazole might do something similar to tumor cells, which divide fast.

The attention exploded after a man in the US said he'd beaten lung cancer while taking it. What often gets left out is that he was also in a clinical trial of an immunotherapy drug at the time. The American Cancer Society makes the fair point that stories like this can be moving without proving anything. When several things are happening at once, you can't tell which one did the work.

Fenbendazole and Liver Cancer: What Does Current Research Show?

It helps to sort the evidence by type, because a result in a petri dish and a result in a patient are very different things.

Laboratory findings

The most direct liver cancer study is a 2022 paper in Biological and Pharmaceutical Bulletin. The researchers treated liver cancer cells (a rat cell line called H4IIE) with fenbendazole and watched what happened. Growth slowed and some cells died, but only in the cells that were actively dividing. Cells that had stopped growing were mostly left alone. The team linked this to a protein called p21, which helps put the brakes on the cell cycle.

It's a neat result. It's also one cell line in one dish, which is a long way from a human liver with a tumor in it.

Animal studies

The animal work is a mixed bag. A 2018 study in Scientific Reports reported that mice fed fenbendazole grew smaller tumors from transplanted human cancer cells. A 2023 study looking at mouse lymphoma found no benefit at all: the tumors grew just as fast as in untreated mice, and the drug seemed to nudge the immune environment in an unhelpful direction. I couldn't find any animal study of fenbendazole in a liver cancer model.

There's also a practical problem. Fenbendazole barely dissolves in water, and a 2024 review in Anticancer Research notes that it struggles to reach the bloodstream at levels that might affect a tumor. ASCO, the American Society of Clinical Oncology, adds that copying the drug concentrations used in the lab would likely take doses well beyond what's safe.

Human evidence

No clinical trial of fenbendazole in people with cancer has been completed. What we have are case reports, and in most of them the patients were getting standard treatment too. One patient's story can't show that a drug caused their outcome.

A related drug is being tested for liver cancer, though. A registered trial is looking at mebendazole added to lenvatinib in advanced hepatocellular carcinoma. That's a different medicine, so it tells us nothing about fenbendazole itself. It just shows the drug family is being explored properly.

Potential Anticancer Mechanisms Under Investigation

Scientists have floated a few ideas about how fenbendazole might work against cancer cells, and all of them come from lab or animal experiments. The first is the one already mentioned: it binds tubulin, only moderately in mammalian cells, and that can stall cell division. Another line of work suggests it changes how cancer cells handle sugar, lowering glucose uptake and interfering with an enzyme called hexokinase II. Not every study agrees on that one, and at least one didn't see the enzyme effect. Some experiments also point to oxidative stress and the switching on of cell-death pathways.

These are working theories. They describe what happened in certain experiments, and they don't tell us what would happen in a patient.

Can Fenbendazole Treat Liver Cancer?

There's no evidence that it can.

Plenty of compounds kill cancer cells in a dish and then do nothing in people. Fenbendazole is at the very beginning of that long road. The treatments we use for liver cancer today, including surgery, ablation, embolization, targeted drugs and immunotherapy, have been through human trials and shown to help. Fenbendazole hasn't.

Is Fenbendazole Approved for Human Cancer Treatment?

No. It's approved for animals only, and neither the FDA nor the European Medicines Agency has approved it for people.

In 2026 ASCO put out a clinical notice on this very question. It says fenbendazole shouldn't be used to treat cancer, or added to standard cancer therapy, outside a well-designed clinical trial. The reasons are no proven benefit, plus the risk of toxicity and harmful interactions with other drugs.

Fenbendazole Safety and Potential Side Effects

In animals, fenbendazole looks well tolerated. In humans, there's very little data. Nobody has worked out a safe dose, and long-term use hasn't been studied.

The best-documented concern is liver injury. Doctors have published several cases. A 67-year-old woman developed severe, biopsy-confirmed liver damage after taking it on her own, and her liver tests took about three months to return to normal once she stopped. An 80-year-old woman with lung cancer, being treated with immunotherapy, developed serious liver injury after taking it because of something she'd seen on social media, and it cleared up after she quit. In 2025, doctors described a 68-year-old man with liver cancer and cirrhosis who became jaundiced after taking it without supervision; that one was a conference abstract, so there's less detail than in a full paper. And a 2026 report described a woman with colon cancer on immunotherapy, where doctors had to work through the timing carefully to tell fenbendazole damage apart from a known side effect of her cancer drug.

Case reports can't say how often this happens. What they do show is that it's real.

Interactions are another open question. The liver breaks fenbendazole down using enzymes, including one called CYP3A4 that also handles many other medicines, so interactions are plausible. But I found no formal interaction studies, so I can't tell you which drugs are affected.

For someone with liver cancer, the stakes are higher. Most liver cancers grow in livers that are already scarred by cirrhosis or chronic hepatitis, and a damaged liver has less room to absorb another hit. Drug injury can also look like the cancer getting worse, which muddies decisions about treatment.

Fenbendazole Tablets and "Fenbendazol Tablete"

Many people searching for fenbendazole tablets have read about it somewhere and want to know what they're looking at. The phrase "fenbendazol tablete" appears to be a spelling used in some Balkan languages, where tablete means tablets.

The tablets on the market are made and labeled for animals. No regulator has set a human dose, a purity standard or a safety profile for them. Nothing here should be read as saying any particular product is safe or effective for people. If you have a diagnosis, or a question about a medicine, a licensed clinician is the right person to ask.

What Should People With Liver Cancer Know?

Tell your care team about everything you take. Vitamins, herbal products, and anything meant for animals all count. That lets your oncologist watch your liver, spot interactions, and avoid blaming the wrong thing when a side effect appears.

Please don't put off or swap out surgery, chemotherapy, immunotherapy, targeted therapy or radiation for something unproven. And if you're curious about newer or repurposed drugs, ask about clinical trials. They offer access to experimental treatments with safety monitoring built in.

Frequently Asked Questions

1. Is fenbendazole effective against liver cancer?

Nobody has shown that. Lab work reports slowed growth in a liver cancer cell line, but there are no human trials.

2. Has fenbendazole been tested in humans with cancer?

Not in clinical trials. There are only case reports, and they can't prove it helped.

3. Is fenbendazole approved for human use?

No. It's approved for animals only. Neither the FDA nor the EMA has approved it for people.

4. What are the potential risks of fenbendazole?

Human safety data are thin. Reported problems include drug-induced liver injury, and its interactions and effects on cancer treatment are unknown.

5. Can fenbendazole cause liver problems?

Several case reports say yes, including one in a patient with liver cancer and cirrhosis. Some people recovered after stopping, but the injuries were sometimes severe.

6. Are fenbendazole tablets safe for humans?

Safety hasn't been established. The tablets available are veterinary products with no human dose or quality standard.

7. What does research say about fenbendazole and cancer?

Lab and some animal studies hint at anticancer activity, but the results are inconsistent and human evidence is missing. ASCO advises against using it outside clinical trials.

8. What is "fenbendazol tablete"?

It looks like a regional-language way of searching for fenbendazole tablets. The same safety and regulatory points apply.

Conclusion

Fenbendazole is a genuinely interesting drug for researchers, and the early lab results, including in liver cancer cells, are reason enough to keep studying it. But for now it's an idea, not a treatment. There are no completed human trials, no approval for use in people, and documented cases of serious liver injury, including in someone with liver cancer.

If you're thinking about fenbendazole, talk to your oncologist first. Whatever you decide, don't let it take the place of care that has been proven to work.